Video length: 2 min.
In research against Alzheimer’s disease, a new drug brings hope. A drug with encouraging effects, but with serious potential side effects.
It is a small bottle of hope. Injected intravenously, this drug has just been approved in the United States to fight Alzheimer’s disease. Her name ? Aducanumab, from the Biogen laboratory. The American Alzheimer’s Association sees this as a solution. “It’s a historic moment and a huge victory for people around the world with Alzheimer’s disease and for their families.“, exults Maria Carrilo, American director of the association.
It is the first treatment approved in the world for 20 years. It is the first treatment approved in the world for 20 years. It attacks a protein that forms plaques around neurons in Alzheimer’s patients and prevents them from functioning normally. Two studies show an improvement in cognitive decline in treated patients. Professor Bruno Dubois, director of memory at the Pitié-Salpêtrière Hospital in Paris, sees it “a very significant reduction in brain lesions (…) untreated patients saw a worsening of their memory and this worsening was not observed in such a severe way in the treated patients.“The treatment must be administered at the very beginning of the disease. But beware, the side effects are not negligible: cerebral edema in a third of cases.